Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 30Other hematologic neoplasm 9Lymphoid 6Plasma cell 3Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Other neoplasm 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

Peripheral Blood Stem Cell Transplantation 8Cyclophosphamide 7fludarabine phosphate 5Whole-Body Irradiation 5Tacrolimus 4Mycophenolic Acid 3Methotrexate 3Melphalan 3Etoposide 3Cyclosporine 3Busulfan 3Antilymphocyte Serum 3Sirolimus 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Carboplatin 2tanespimycin 1sargramostim 1ruxolitinib 1pyroxamide 1fludarabine 1aldesleukin 1Topotecan 1Tetradecanoylphorbol Acetate 1Radiotherapy 1Prednisone 1Phenytoin 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × ruxolitinib × Other neoplasm × Clear all
NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡